Table 2.
Anatomical and functional outcomes.
| Stage of disease | Number of eyes at baseline
N (%) |
Pre BCVA
Mean (SD) |
Number of eyes received treatment/observed | Mode of treatment (N) | Final BCVA
Mean (SD) |
Number of eyes at final follow-up
N (%) |
Number of eyes with final BCVA >20/200 | Anatomical outcome (nos) (N) |
|---|---|---|---|---|---|---|---|---|
| 1 | 5 (3.4) | 1.04 (1.381) | 5/0 | Cryo 3
Laser 3 Steroid 4 Anti-VEGF 0 |
0.88 (0.756) | 16 (10.8) | 50% (2/4) | Good – 4
Absolute eye – 0 Phthisis bulbi – 1 |
| 2A | 25 (16.9) | 1.54 (1.207) | 19/6 | Cryo 9
Laser 12 Steroid 10 Anti-VEGF 4 |
1.44 (1.15) | 48 (32.4) | 26.08% (6/23) | Good – 22
Absolute eye – 3 Phthisis bulbi – 0 |
| 2B | 33 (22.3) | 1.98 (1.17) | 26/7 | Cryo 9
Laser 17 Steroid 4 Anti-VEGF 9 |
1.55 (1.09) | 14 (9.5) | 23.33% (7/30) | Good – 30
Absolute eye – 2 Phthisis bulbi – 1 |
| 3A | 19 (12.2) | 1.99 (1.35) | 11/8 | Cryo 5
Laser 7 Steroid 7 Anti-VEGF 7 |
1.18 (.92) | 12 (8.1) | 47.05% (8/17) | Good – 16
Absolute eye – 3 Phthisis bulbi – 0 |
| 3B | 47 (31.8) | 2.55 (1.2) | 31/16 | Cryo 13
Laser 20 Steroid 2 Anti-VEGF 4 |
2.57 (1.2) | 29 (19.5) | 34.28% (12/35) | Good – 34
Absolute eye – 10 Phthisis bulbi – 3 |
| 4 | 4 (2.7) | 2.23 (1.5) | 3/1 | Cryo 3
Laser 1 Steroid 0 Anti-VEGF 0 |
1.2 (.42) | 3 (2) | 0% (0/3) | Good – 4
Absolute eye – 0 Phthisis bulbi – 0 |
| 5 | 15 (10.1) | 3.5 (.53) | 12/3 | Cryo 7
Laser 4 Steroid 8 Anti-VEGF 5 |
3.67 (.51) | 26 (17.6) | 0% (0/12) | Good – 13
Absolute eye – 2 Phthisis bulbi – 0 |
BCVA, best-corrected visual acuity; SD, standard deviation; VEGF, vascular endothelial growth factor.